ArticleInternational journal of nanomedicine2026
Glioma Cell Membrane-Coated CaCO
Article in International journal of nanomedicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Biomimetic membrane-coated metal nanoplatforms for enhanced BBB penetration and targeted glioblastoma therapy.International journal of pharmaceutics: X · 2026Review
- Engineered nanomedicine remodels the postoperative cavity microenvironment to suppress glioblastoma recurrence.Theranostics · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Postoperative recurrence of glioma remains a major clinical challenge due to the blood-brain barrier and an immunosuppressive tumor microenvironment, necessitating innovative local treatment strategies. Methods: We developed a biomimetic nanoplatform (CaDM) by coating doxorubicin (DOX)-loaded calcium carbonate nanoparticles with a glioma cell membrane. This construct was then integrated with the clinical hemostatic agent Surgiflo to create an in-situ forming depot for localized application into the tumor resection cavity. Results: The CaDM nanoparticles exhibited excellent acid-responsive degradation, enabling simultaneous release of DOX and Ca Conclusion: This work presents a readily translatable and multifaceted nanomedicine approach that effectively prevents glioma recurrence through synergistic calcium overload and immunomodulation, offering a promising novel strategy for local tumor treatment.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.